Royalty Pharma (RPRX) Q4 FY25 earnings call: guidance and Q&A

How sustainable is the 2025 step-up in dividends/buybacks, and could that capital have been better spent on royalty deals? Also, with thawing capital markets, will Royalty Pharma get more involved in private/crossover/IPO opportunities?

Terry Coyne explained the dynamic capital allocation framework, prioritizing royalty opportunities but also using buybacks when the stock is undervalued. Chris Hite noted their focus on high-quality assets regardless of whether they are housed in private or public companies, and that the opportunity set has grown in all market environments.

“Right now, I would say we feel really, really excited about the pipeline and the opportunities for royalties. But we're going to continue to return capital to shareholders via share repurchases and dividends. But I think the priority right now is probably a little bit more biased towards the royalties.”

asked by Jeff Meacham · answered by Terrance Coyne

How has Alyftrek's conversion of CF patients tracked relative to assumptions, and how long to reach peak conversion? Also, in general medicine/cardiometabolic, what's Royalty Pharma's view on long-acting injectables vs. daily orals for commercial opportunity, and would they diversify or show strong opinion on drug delivery format?

Terry Coyne stated Alyftrek conversion has been gradual but steady, consistent with their expectations, and the CF franchise is expected to remain a strong contributor ($800M in Royalty Receipts by 2030). Marshall Urist noted excitement for general medicine/cardiometabolic, seeing opportunities for diverse product profiles (injectables/orals) due to large market size and patient needs, and they will seek differentiated products with strong marketers.

“I think by and large, it's been pretty consistent with what we thought. It has -- it's been gradual but steady. I think it's tough for us to speculate at this point on what percent will ultimately go to Alyftrek, but I think either way, what we laid out at our Investor Day, I think, is how we think about it long term, where we think that by 2030, even with a lot of patients switching to Alyftrek and under a downside case where we are not successful in the arbitration that we still would recognize Portfolio Receipt -- or Royalty Receipts from the CF franchise of around $800 million.”

asked by Michael Nedelcovych · answered by Terrance Coyne

Will synthetic royalties continue to exceed traditional royalties in mix this year? And what are the implications of Novartis' Lp(a) trial delay for likelihood of success and for Amgen's later readout?

Chris Hite confirmed strong excitement for the synthetic royalty market, expecting continued growth due to its benefits over traditional financing. Marshall Urist stated no change in enthusiasm for Lp(a), attributing the Novartis trial delay to event rate uncertainty in a first-in-class outcomes trial, and it doesn't change their view on the class's potential.

“So to see it kind of shifting around a little bit here is not -- it doesn't come as a particularly surprise to us and doesn't change our view. We're still eagerly awaiting the results from Novartis this year.”

asked by Terence Flynn · answered by Marshall Urist

Which assets in the broader portfolio are most underappreciated by Wall Street models? And what is the update on the China opportunity, specifically when could it become a funnel into the transaction pipeline?

Marshall Urist highlighted the aggregate potential of the pipeline ($2B+ non-risk-adjusted peak royalties) as underappreciated, specifically mentioning Biogen's litifilimab, Sanofi's frexalimab, and J&J's depression product. Chris Hite reiterated excitement for China, noting increasing out-licensing deals and their plan to expand locally to source deals, with the expectation that these earlier-stage assets will eventually enter their funnel.

“When you look across here, we do get a significant number of questions on Lp(a) and Revolution Medicines. But the other ones, we -- the other products we highlighted here, Biogen's litifilimab, we'll have Phase III results here coming up. Sanofi, frexalimab, we've highlighted the non -- the post CD20 or non-CD20 part of the market and the real need for new targets in MS is exciting to us. And then another product that we highlighted was J&J, a depression product that is a little -- that is off the radar, but J&J has put a lot of development resources into, and we'll have data for that next year.”

asked by Asad Haider · answered by Marshall Urist

What attracted Royalty Pharma to Teva's IL-15 asset, and does this indicate a trend towards earlier-stage assets? Also, how is Voranigo's growth expected to continue, and what is its potential as an asset?

Marshall Urist explained Teva's IL-15 deal was attractive due to unmet need in vitiligo, strong science (IL-15 target), and blockbuster potential. He clarified it's not a trend to earlier stages but a creative tranches structure to fund Phase IIb and then Phase III. For Voranigo, he expressed continued excitement for its strong launch and potential as a blockbuster product due to profound unmet need and long duration of therapy for low-grade gliomas.

“We're making a relatively small investment here to help fund the Phase IIb of $75 million. And then we will have following that, the option to significantly scale up that investment to help fund the Phase III. So that's a very powerful mechanism to us and a very powerful structure.”

asked by Christopher Schott · answered by Marshall Urist

How is Royalty Pharma thinking about the potential implications of the upcoming Myqorzo non-obstructive HCM study, given heterogeneity and prior failures? Is the 2026 operating/professional cost run rate a good long-term indicator, or are there further internalization impacts?

Marshall Urist stated Myqorzo's non-obstructive HCM study is an upside driver, as their base case for investment was the obstructive indication. He noted Cytokinetics has learned from Camzyos' experience. Terry Coyne confirmed the 2026 operating cost guidance (5.5%-6.5% of Portfolio Receipts) reflects significant internalization savings and they remain on track for a long-term target of 4%-5%.

“our base case when we made this investment was it was premised on the currently approved indication of obstructive disease. So that -- we did not assume that this trial turned out positively when we made the investment.”

asked by Ashwani Verma · answered by Marshall Urist

Does J&J's oral IL-23 represent market expansion or cannibalization risk for Tremfya? How does Royalty Pharma view Trelegy's contribution given GSK's investment in longer-acting options?

Marshall Urist sees J&J's oral IL-23 as market expanding, not cannibalizing Tremfya, as both are strong products with significant potential, and an oral option can serve different patient needs. For Trelegy, he expects continued strong growth, noting GSK's robust respiratory franchise and that Trelegy's performance has consistently outperformed expectations.

“We definitely see it as market expanding. I think that, that is a great product, but Tremfya is a great product as well, and you're seeing that in the very strong momentum in the inflammatory bowel disease launch for Tremfya.”

asked by Michael DiFiore · answered by Marshall Urist

How might future China deal structures differ, and are there added diligence hurdles? How important is a 15%-20% risk reduction for Lp(a) to commercial peak sales?

Pablo Legorreta stated no foreseen change in China deal structures or diligence process, as they typically buy royalties from Chinese companies that have licensed products to US/European marketers, making the payer a Western entity. Marshall Urist confirmed effect size matters for Lp(a), and there will be discussion on the specific reduction, patient subgroups, and overall benefit, but the market is large enough for various profiles.

“There's no question, and it won't surprise you to hear us say that the effect size does matter. I think we should -- given that we're a few months away at this point from seeing this data, I think there will be a lot of discussion, I am sure, based on what it ultimately shows.”

asked by Dina Ramadane · answered by Marshall Urist